Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 148

1.

Induced pluripotent stem cells--opportunities for disease modelling and drug discovery.

Grskovic M, Javaherian A, Strulovici B, Daley GQ.

Nat Rev Drug Discov. 2011 Nov 11;10(12):915-29. doi: 10.1038/nrd3577. Review.

PMID:
22076509
2.

Stem cells as in vitro model of Parkinson's disease.

Martínez-Morales PL, Liste I.

Stem Cells Int. 2012;2012:980941. doi: 10.1155/2012/980941. Epub 2012 Apr 30.

3.

New lessons learned from disease modeling with induced pluripotent stem cells.

Onder TT, Daley GQ.

Curr Opin Genet Dev. 2012 Oct;22(5):500-8. doi: 10.1016/j.gde.2012.05.005. Epub 2012 Jun 28. Review.

4.

Disease-specific induced pluripotent stem cells: a platform for human disease modeling and drug discovery.

Jang J, Yoo JE, Lee JA, Lee DR, Kim JY, Huh YJ, Kim DS, Park CY, Hwang DY, Kim HS, Kang HC, Kim DW.

Exp Mol Med. 2012 Mar 31;44(3):202-13. doi: 10.3858/emm.2012.44.3.015.

5.

Disease modeling and drug screening for neurological diseases using human induced pluripotent stem cells.

Xu XH, Zhong Z.

Acta Pharmacol Sin. 2013 Jun;34(6):755-64. doi: 10.1038/aps.2013.63. Epub 2013 May 20. Review.

6.

A new era of disease modeling and drug discovery using induced pluripotent stem cells.

Suh W.

Arch Pharm Res. 2017 Jan;40(1):1-12. doi: 10.1007/s12272-016-0871-0. Epub 2016 Dec 5. Review.

PMID:
27921262
7.

iPSC technology: platform for drug discovery. Point.

Ellis J, Bhatia M.

Clin Pharmacol Ther. 2011 May;89(5):639-41. doi: 10.1038/clpt.2011.22.

PMID:
21512521
8.

Concise review: drug discovery in the age of the induced pluripotent stem cell.

Ko HC, Gelb BD.

Stem Cells Transl Med. 2014 Apr;3(4):500-9. doi: 10.5966/sctm.2013-0162. Epub 2014 Feb 3. Review.

9.

Recent Advances in Disease Modeling and Drug Discovery for Diabetes Mellitus Using Induced Pluripotent Stem Cells.

Kawser Hossain M, Abdal Dayem A, Han J, Kumar Saha S, Yang GM, Choi HY, Cho SG.

Int J Mol Sci. 2016 Feb 19;17(2):256. doi: 10.3390/ijms17020256. Review.

10.

Novel stem cell-based drug discovery platforms for cardiovascular disease.

Adams WJ, García-Cardeña G.

J Biomol Screen. 2012 Oct;17(9):1117-27. Epub 2012 Aug 1. Review.

PMID:
22853930
11.

The use of induced pluripotent stem cells in drug development.

Inoue H, Yamanaka S.

Clin Pharmacol Ther. 2011 May;89(5):655-61. doi: 10.1038/clpt.2011.38. Epub 2011 Mar 23. Review.

PMID:
21430656
12.

iPSCs and small molecules: a reciprocal effort towards better approaches for drug discovery.

Zhang R, Zhang LH, Xie X.

Acta Pharmacol Sin. 2013 Jun;34(6):765-76. doi: 10.1038/aps.2013.21. Epub 2013 Apr 22. Review.

13.

Human-induced pluripotent stem cell models of inherited cardiomyopathies.

Karakikes I, Termglinchan V, Wu JC.

Curr Opin Cardiol. 2014 May;29(3):214-9. doi: 10.1097/HCO.0000000000000049. Review.

14.

Disease modelling using induced pluripotent stem cells: status and prospects.

Pomp O, Colman A.

Bioessays. 2013 Mar;35(3):271-80. doi: 10.1002/bies.201200088. Epub 2012 Nov 13. Review.

PMID:
23148027
15.

Astrocytes generated from patient induced pluripotent stem cells recapitulate features of Huntington's disease patient cells.

Juopperi TA, Kim WR, Chiang CH, Yu H, Margolis RL, Ross CA, Ming GL, Song H.

Mol Brain. 2012 May 21;5:17. doi: 10.1186/1756-6606-5-17.

16.

Can stem-cell-derived models revolutionize drug discovery?

Landgren H, Sartipy P.

Expert Opin Drug Discov. 2014 Jan;9(1):9-13. doi: 10.1517/17460441.2014.867945. Epub 2013 Dec 6.

PMID:
24308376
17.

Induced Pluripotent Stem Cells for Disease Modeling and Drug Discovery in Neurodegenerative Diseases.

Cao L, Tan L, Jiang T, Zhu XC, Yu JT.

Mol Neurobiol. 2015 Aug;52(1):244-55. doi: 10.1007/s12035-014-8867-6. Epub 2014 Aug 23. Review.

PMID:
25146848
18.

Toxicity testing and drug screening using iPSC-derived hepatocytes, cardiomyocytes, and neural cells.

Csöbönyeiová M, Polák Š, Danišovič L.

Can J Physiol Pharmacol. 2016 Jul;94(7):687-94. doi: 10.1139/cjpp-2015-0459. Epub 2016 Feb 1. Review.

PMID:
27128322
19.

Induced pluripotent stem cell technology for disease modeling and drug screening with emphasis on lysosomal storage diseases.

Huang HP, Chuang CY, Kuo HC.

Stem Cell Res Ther. 2012 Aug 28;3(4):34. doi: 10.1186/scrt125. Review.

20.

Modelling the long QT syndrome with induced pluripotent stem cells.

Itzhaki I, Maizels L, Huber I, Zwi-Dantsis L, Caspi O, Winterstern A, Feldman O, Gepstein A, Arbel G, Hammerman H, Boulos M, Gepstein L.

Nature. 2011 Mar 10;471(7337):225-9. doi: 10.1038/nature09747. Epub 2011 Jan 16.

PMID:
21240260

Supplemental Content

Support Center